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ABSTRACT  
 
OBJECTIVE  
The objective of this selective EBM review is to determine whether or not memantine is a safe 
and effective treatment for Alzheimer’s disease in patients over the age of 50. 
STUDY DESIGN  
Systematic review of two randomized controlled trials published in 2006 and 2013 and one 
randomized controlled trial pooled analysis published in 2014. 
DATA SOURCES  
Two randomized controlled trials and one pooled analysis were obtained using PubMed.  
OUTCOMES MEASURED  
Efficacy of memantine as compared to control groups based on cognition, behavior, and adverse 
events. These were measured using Severe Impairment Battery (SIB), Neuropsychiatric 
Inventory (NPI), and Behavioral Pathology in AD Rating Scale (BEHAVE-AD). 
RESULTS  
Herrmann et al. (2013) and Peskind et al. (2006) failed to show superiority of memantine over a 
placebo. Nakamura et al. (2014) showed that memantine produced statistically better outcomes 
compared to the placebo in terms of behavior and cognitive function. In all three studies, the 
overall incidence of adverse events was similar between the memantine and placebo groups.  
CONCLUSION  
The trials analyzed in this selective EBM review showed conflicting evidence regarding the 
efficacy of memantine in the treatment of Alzheimer’s disease. Further investigation is warranted 
to definitively evaluate the efficacy of memantine at improving cognition and behavior. 
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INTRODUCTION 
Alzheimer’s disease is a progressive and degenerative neurological disorder characterized 
by a decline in cognition, function, behavior, and ability to perform activities of daily living.1 It 
affects an estimated 5.5 million Americans, and approximately one in 10 people over the age of 
65 has Alzheimer’s disease.2 In 2017, Alzheimer’s cost the nation $259 billion.2 An exact 
number of healthcare visits each year has not been identified; however, a person with dementia 
in 2012 had an annual average of 22.5 inpatient days.2 The exact etiology of Alzheimer’s disease 
is unknown, but the structural manifestations of the disease have been identified. These include 
extracellular amyloid plaques, intraneuronal neurofibrillary tangles, synaptic loss, neuronal 
death, and changes in the glutamatergic and cholinergic pathways.1 The exact role of plaques and 
tangles is unknown, but most experts believe they play a critical role in blocking communication 
among nerve cells and disrupting cell survival processes.3  
These structural manifestations contribute to the cardinal symptoms of Alzheimer’s 
disease including memory impairment, executive function impairment, and neuropsychiatric 
symptoms.4 The standard medical treatment for Alzheimer’s includes cholinesterase inhibitors 
and partial N -methyl-D-aspartate antagonists.5 Symptomatic therapies are available but they do 
not act on the evolution of the disease. Secondary symptoms such as depression, agitation, 
aggression, hallucinations, delusions, sleep disorders are treated with the following: 
antidepressants, anxiolytics, antiparkinsonian agents, beta-blockers, antiepileptic drugs, and 
neuroleptics.5 Currently, there is no cure for Alzheimer’s disease; however, the medications 
listed above have seemed to improve symptoms in patients.5  
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not memantine is a 
safe and effective treatment for Alzheimer’s disease in patients over the age of 50. 
METHODS 
This systematic review consists of two double-blind, randomized, controlled trials and 
one pooled analysis of two randomized, double-blind, placebo-controlled trials comparing the 
safety and efficacy of memantine as a treatment of Alzheimer’s disease.  The study population of 
the trials and pooled analysis consists of men and women over the age of 50 with Alzheimer’s 
disease. The populations excluded from these studies are patients under the age of 50, those with 
an unstable medical condition, those with other psychiatric or neurological disorders, and those 
with a Hachinski Ischemia score > 4. Keywords used in the research for these studies include 
memantine and Alzheimer’s disease.  All articles used in this research are peer-reviewed journals 
published in English and were found via PubMed. Articles were selected based on their 
relevance to my clinical question and if they included patient oriented outcomes. They must have 
been published in 2006 or later. Exclusion criteria included articles published prior to the year 
2006, articles that were not primary research in nature, or if they focused on disease oriented 
outcomes.  Statistics used in the articles include RRI, ARI, NNH, mean change from baseline, p-
value, and 95% CI. Table 1 below displays the demographics and characteristics of the studies 
that were reviewed. 
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Table 1:  Demographics & characteristics of included studies 
Study Type # Pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria  
W/D Intervention  
Herrmann6 
(2013) 
RCT 369 ≥ 50 -MMSE 8-18, 
ongoing ChEI 
therapy, 
knowledgeable 
and reliable 
caregiver, 
residence in 
the 
community, 
stable medical 
condition, NPI 
total ≥13 and 
NPI agitation/ 
aggression 
score ≥1  
-unstable medical 
condition, other 
psychiatric or 
neurological 
disorder, vascular 
dementia, 
modified 
Hachinski 
Ischemia score > 
4  
 
63 Memantine 
20 mg 
Peskind1 
(2006) 
RCT 403 ≥ 50 -MMSE 10-
22, CT or MRI 
consistent w/ 
Alzheimer’s, 
knowledgeable 
and reliable 
caregiver, 
MADRS score 
<22, 
ambulatory, 
medically 
stable 
-unstable medical 
condition, other 
psychiatric or 
neurological 
disorder, 
Hachinski 
Ischemia score > 
4, delusions or 
delirium, cancer, 
substance abuse 
71 Memantine 
20 mg 
Nakamura7 
(2014) 
RCT 
pooled 
analysis 
640 ≥ 50 -MMSE 5-14, 
CT or MRI 
consistent w/ 
Alzheimer’s, 
moderate to 
severe 
Alzheimer’s, 
consistent 
caregiver  
-serious 
neurological 
psychiatric 
disorder, history 
of treatment with 
memantine, 
planning to move 
to nursing home  
7 Memantine 
20 mg 
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OUTCOMES MEASURED 
Cognition was measured using the Severe Impairment Battery (SIB), which is a validated 
scale used to assess cognitive function in patients with moderate-to-severe dementia.6 Behavior 
was measured using the Neuropsychiatric Inventory (NPI) and the Behavioral Pathology in AD 
Rating Scale (BEHAVE-AD). The NPI is a 12-item scale that assesses frequency and severity of 
behavioral symptoms in patients with dementia.1 The BEHAVE-AD evaluates behavioral and 
psychological symptoms of dementia using the following seven subdomains: paranoid and 
delusional ideation, hallucinations, activity disturbances, aggressiveness, diurnal rhythm 
disturbances, affective disturbance, and anxieties and phobias.7  
Adverse events measured in the studies include the following: nausea, vomiting, diarrhea, 
decreased weight, fall, dizziness, depression, contusion, inflicted injury, insomnia, upper 
respiratory infections, agitation, and somnolence.1,6,7 In the Herrmann study, the NPI was 
assessed at screening, baseline, week 4, week 8, week 12, week 18, and week 24. The SIB was 
assessed at baseline, week 12, and week 24. In the Peskind study, the NPI was assessed at 
baseline, week 12, week 24, and at the endpoint using a last observation carried over approach 
(LOCF). In the Nakamura study, both the SIB-J (Japanese equivalent of SIB) and BEHAVE-AD 
were assessed at baseline, week 4, week 12, week 24, and at the endpoint using a LOCF 
approach. In all of the studies, adverse events were recorded at baseline and each subsequent 
visit. This selective EBM review will focus on the results at week 24 and total adverse events for 
each study.  
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RESULTS 
 In both randomized controlled trials and the pooled analysis, the efficacy and safety of 
memantine is compared to a placebo. In the Herrmann study, a total of 369 patients entered the 
study and 306 patients completed the study. The exclusion parameters for this study included 
patients with an unstable medical condition, other psychiatric or neurological disorder, vascular 
dementia, or a modified Hachinski Ischemia score > 4. The patients were all males and females ≥ 
50 years of age with Alzheimer’s severity at baseline ranging from moderate to severe. The mean 
age of patients was 75 years. Of the 369 patients who entered the study, 187 were randomized to 
placebo and 182 were randomized to memantine in accordance with a randomization list 
generated by the sponsor following a standard routine. Patients receiving memantine were 
titrated in 5 mg weekly increments from a starting dose of 5 mg/day to 20 mg day administered 
once daily at the beginning of week 4. Active drug and placebo tablets were visually identical 
and all patients received four tablets of study medication daily. The mean change from baseline 
for NPI was -3.901.24 for the memantine group and 5.131.23 for the placebo group. The mean 
change from baseline for SIB was -2.340.76 for the memantine group and -1.860.75 for the 
placebo group. The mean change from baseline, CI, and p-values are reported in Tables 2-3.   
 
Table 2. Statistical results of the Severe Impairment Battery (SIB) to assess cognitive function6,7 
Study  95% CI P-value Mean change 
from baseline at 
week 24: 
memantine 
Mean change 
from baseline 
at week 24: 
placebo 
Herrmann -2.3 to 1.34 0.60 -2.340.76 -1.860.75 
Nakamura Not reported  <0.0001 -0.25 -4.38 
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Table 3. Statistical results of the Neuropsychiatric Inventory (NPI) and the Behavioral Pathology 
in AD Rating Scale to assess behavior1,6,7 
Study  95% CI P-value Mean change 
from baseline at 
week 24 
Mean change 
from baseline 
at week 24: 
placebo 
Herrmann -1.75 to 4.21 0.42 -3.901.24 -5.131.23 
Peskind -4.9 to 0.7 0.14 -1.2 0.9 
Nakamura Not reported  0.0040 -0.52 0.52 
 
The values for mean change from baseline in the Herrmann study are small given the nature of 
this study, so there is not a big difference in the patient’s behavior, cognition, and function after 
taking memantine. The p-value is 0.42 for the NPI and 0.60 for the SIB. Since these values are 
greater than 0.05, the results were not statistically significant. The 95% CI is -2.3 to 1.34 for SIB 
and -1.75 to 4.21 for NPI. Adverse events reported during the study are included below in Table 
4.  
Table 4. Adverse events in the Herrmann study with an incidence ≥5% in either treatment group 
(all-patients-treated set)6 
 
Adverse event  Memantine (N=182) 
N (%) 
Placebo (N=187) 
N (%) 
Fall 20 (11.0) 8 (4.3) 
Agitation 15 (8.2) 7 (3.7) 
Weight decreased 11 (6.0) 5 (2.7) 
Somnolence 10 (5.5) 5 (2.7) 
Nausea 4 (2.2) 11 (5.9) 
Total adverse events  138 (75.8) 136 (72.7) 
 
 
The incidence of adverse events considered related to the study drug was 30% in the placebo 
group and 36% in the memantine group, so the number of adverse events were similar between 
the two groups. The calculations for harm include relative risk increase (RRI), absolute risk 
increase (ARI), and numbers needed to harm (NNH). These calculations are reported in Table 5.  
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Table 5. Comparison and statistical significance of outcomes measured of included studies1,6,7  
Study RRI ARI NNH 
Herrmann 66.7% 4% 25 patients  
Peskind 90% 4.5% 23 patients  
Nakamura 2.2% 1.7% 59 patients  
 
In the Herrmann study, memantine increases a patient’s risk of having an adverse event by 
66.7%, and for every 25 patients, 1 additional patient would also experience an adverse event. 
In the Peskind study, 403 patients were recruited from 42 U.S. sites, 332 patients 
completed the study, and 394 patients were included in the primary analysis. The exclusion 
parameters for this study included unstable medical condition, other psychiatric or neurological 
disorder, Hachinski Ischemia score > 4, delusions or delirium, cancer, or substance abuse. The 
patients were all males and females ≥ 50 years of age with Alzheimer’s severity at baseline 
ranging from mild to moderate. The mean age was 77 for the placebo group and 78 for the 
memantine group. Patients were randomized to memantine or placebo groups in permuted blocks 
of four in accordance with the randomization list generated and retained by Forest Research 
Institute Department of Statistical Programming.  All participants assigned to the memantine 
group received an initial dose of 5 mg per day; the dose was titrated in 5-mg weekly increments 
to a final dose of 20 mg/day (administered as two 5-mg tablets twice a day) on day 22.  The 
placebo and memantine tablets were visually identical, and all participants received four tablets 
of study medication daily. The mean change from baseline, CI, and p-values are reported above 
in Tables 2-3. The mean change from baseline using the last observation carried forward (LOCF) 
approach at week 24 for NPI is -1.2 for memantine and 0.9 for the placebo.  
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Although the analysis favored memantine over the placebo, the results were not 
statistically significant. The p-value is 0.14 for the NPI, which indicates the estimate of treatment 
effect is not precise. The 95% CI is -4.9 to 0.7 for NPI. The adverse events reported during the 
trial are listed below in Table 6.  
Table 6. Adverse events in the Peskind study with an incidence of  ≥5.0% in either treatment 
group1 
Adverse event Placebo (N=202)  
N (%) 
Memantine (N=201) P Value  
Fall 15 (7.4) 15 (7.5) 1.00 
Agitation 12 (5.9) 15 (7.5) 0.56 
Influenza-like 
symptoms 
13 (6.4%) 14 (7.0) 0.85 
Somnolence  2 (1.0) 14 (7.0) 0.002 
Headache 9 (4.5) 13 (6.5) 0.39 
Inflicted injury 11 (5.4) 12 (6.0) 0.83 
Confusion 7 (3.5) 10 (5.0) 0.47 
Dizziness  9 (4.5) 10 (5.0) 0.82 
Hypertension 11 (5.4) 9 (4.5) 0.82 
Depression 10 (5.0) 4 (2.0) 0.17 
Upper respiratory 
infection 
12 (5.9) 4 (2.0) 0.07 
 
Adverse events occurred in 74% of the placebo group and 71% of the memantine group, so the 
number of adverse events were similar between the two groups. The calculations for harm are 
reported above in Table 5. In the Peskind study, memantine increases a patient’s risk of having 
an adverse event by 90% and for every 23 patients, 1 additional patient would also experience an 
adverse event. 
In the Nakamura pooled analysis, 640 patients were analyzed from various Japanese 
institutions. Of those 640 patients, 321 were treated with memantine and 319 were treated with 
the placebo. The final analysis comprised 633 patients with 318 receiving memantine and 315 
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receiving placebo. Seven patients were excluded from the pooled analysis due to a lack of post-
baseline efficacy measurements. The exclusion parameters for this study included serious 
neurological psychiatric disorder, history of treatment with memantine, or planning to move to a 
nursing home. The patients were all males and females ≥ 50 years of age with Alzheimer’s 
severity at baseline ranging from moderate to severe. The mean age was 74.5 for the placebo 
group and 74 for the memantine group. Patients were randomized to memantine or placebo 
groups. All participants assigned to the memantine group received an initial dose of 5 mg per 
day; the dose was titrated in 5-mg weekly increments to a final dose of 20 mg/day. The placebo 
and memantine tablets were visually identical. The mean change from baseline, CI, and p-values 
are reported above in Tables 2-3. The mean change from baseline using the last observation 
carried forward (LOCF) approach for BEHAVE-AD was -0.52 for the memantine group and 
0.52 for the placebo group. The mean change from baseline for SIB was -0.25 for the memantine 
group and -4.38 for the placebo group. Memantine produced statistically better outcomes 
compared to the placebo in both behavior and cognitive function. The p-value is <0.0001 for the 
SIB and 0.0067 for the BEHAVE-AD, so the estimate of treatment effect is precise. The adverse 
events reported during the trials are listed below in Table 7.  
Table 7. Adverse events in the Nakamura study with an incidence of ≥ 5% in either treatment 
group7 
Adverse events Memantine (N=321) 
N (%) 
Placebo (N=319) 
N (%) 
Constipation 37 (11.5) 33 (10.3) 
Diarrhea 14 (4.4) 18 (5.6) 
Vomiting 10 (3.1) 12 (5.3) 
Nasopharyngitis  46 (14.3) 54 (16.9) 
Fall 31 (9.7) 33 (10.3) 
Contusion 18 (5.6) 20 (6.3) 
Insomnia 18 (5.6) 16 (5.0) 
Total adverse events  252 (78.5) 245 (76.8) 
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Adverse events occurred in 78.5% of the memantine group and 76.8% of the placebo group, so 
the number of adverse events were similar between the two groups. The calculations for harm are 
reported above in Table 5. In the Nakamura study memantine increases a patient’s risk of having 
an adverse event by 2.2% and for every 59 patients, 1 additional patient would also experience 
an adverse event. 
DISCUSSION 
 This systematic review assessed the efficacy and safety of memantine compared to a 
placebo as a treatment for Alzheimer’s disease in terms of cognition, behavior, and adverse 
events. The two randomized controlled trials failed to show superiority of memantine over a 
placebo; however, the pooled analysis showed that memantine produced statistically better 
outcomes compared to the placebo in terms of behavior and cognitive function. In all three 
studies, the overall incidence of adverse events was similar between the memantine and placebo 
groups.  
There were several limitations noted with each study. In the Herrmann study, there was 
under-recruitment which resulted in a decreased statistical power to show the superiority of 
memantine over placebo.6 This study was amended a total of seven times with implications on 
the patient population selected.6 There were higher agitation scores in the memantine group and 
lower exposure to antipsychotics and antidepressants in the placebo group, so several baseline 
differences existed.6 Patients were already severely behaviorally impaired, so worsening was less 
likely. This reduced the opportunity to demonstrate a drug–placebo benefit.6 In the Peskind 
study, patients in the placebo group who worsened left the trial before they could be measured at 
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the end point which influenced the results.1 In the Nakamura study, a potential limitation relates 
to the information obtained from the caregivers on the status of the patient.7 For those patients in 
the study who used long-term care services, information from only one caregiver might have 
been insufficient to reflect actual changes in clinical symptoms.7  
Memantine is used in over 80 countries worldwide and has been used to treat patients 
with Alzheimer’s for over 10 years.7 It is approved by the U.S. Food and Drug Administration 
and the EMEA for the treatment of moderate to severe Alzheimer’s.1 Memantine is widely 
available in the United States, so insurance and access to the study drug were non-issues and did 
not affect the results of the studies.  
CONCLUSION 
The trials analyzed in this selective EBM review showed conflicting evidence regarding 
the efficacy of memantine in the treatment of Alzheimer’s disease. The Nakamura study 
demonstrated the most convincing data that memantine improves cognition and behavior and 
was also the largest study analyzing this topic. The Peskind study favored memantine over the 
placebo, but the results were not statistically significant. The Herrmann study failed to show 
superiority of memantine over the placebo. In all three studies, the incidence of adverse events 
was similar between memantine and the placebo. Future investigation is warranted to definitively 
evaluate the efficacy of memantine at improving cognition and behavior. It would be beneficial 
to have a larger study group with more similar baselines among participants.
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